-+ 0.00%
-+ 0.00%
-+ 0.00%

Candel Therapeutics reports 25.4-month median overall survival and 50% 24-month survival in CAN-2409 phase 2a NSCLC trial

Reuters·03/17/2026 12:06:17

Please log in to view news